Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study
Dandan Wang, et al. (Beike Biotechnology Co., Ltd.)
Arthritis Research & Therapy 2014, 16:R79
Conclusion: UC-MSCT results in satisfactory clinical response in SLE patients.
However, in our present study, several patients experienced disease relapse after 6 months, indicating the necessity to repeat MSCT after 6 months.
MSCs are multipotent, nonhematopoietic progenitor cells that are currently being explored as a promising new treatment for tissue regeneration. Although their immunomodulatory properties are not yet completely understood, their low immunogenic potential, together with their effects on immune responses, make them a promising therapeutic tool for the treatment of patients with severe and refractory autoimmune diseases.
Stem-Cell Therapy in China Draws Foreign Patients
March 18, 2008